Shyh T P, Beyer M M, Friedman E A
Nephron. 1985;40(2):129-38. doi: 10.1159/000183448.
Improved patient survival and rehabilitation have been continuously reported over the last decade for diabetics in irreversible kidney failure. There have, however, been no controlled prospective trials of the relative merits of CAPD, maintenance hemodialysis, or kidney transplantation in the uremic diabetic. As a generalization, younger, more rehabilitatable diabetics have been offered a kidney transplant, while older, often sicker diabetics have been relegated to CAPD, leaving most diabetics in the subset managed by maintenance hemodialysis. Treatment preference has reasonably been based on a team's experience and available facilities. Furthermore, nonuniform criteria for patient selection, and timing of the onset of uremia therapy, preclude direct comparisons between series of treated diabetics. While survival of diabetics treated with maintenance hemodialysis or peritoneal dialysis has improved substantially in recent years, survival and rehabilitation after kidney transplantation are superior to other forms of uremia therapy. Cumulative data suggest that a treated uremic diabetic patient has a 50% chance of living 3 years on hemodialysis, a 50% chance of surviving 5 years if he receives a well functioning cadaveric kidney transplant, and an even longer anticipated survival of 50% for 7.5 years if transplanted with a well-functioning living-related kidney. Even better results may be attainable with kidneys from HLA-identical siblings, particularly when transplanted early and employing cyclosporine rather than azathioprine, thereby allowing reduction of steroid dosage to minimal levels. Kidney transplantation, when judiciously undertaken by a team skilled in overall diabetic management, is the treatment of choice for the uremic diabetic. Dialytic therapy, however, has appreciable value, not only as an alternative in patients in whom transplantation is contraindicated, or for whom a kidney is not available, but as life-sustaining therapy while awaiting surgical intervention. No matter how treated, diabetic nephropathy need no longer be viewed as a disease of desperation. Unfortunately, proffering a substitute for the diabetic patient's own renal function does not, in and of itself, diminish progression of preexisting multisystem micro- and macrovascular disease. Implantation of a functioning kidney transplant in a failing diabetic with the renal-retinal syndrome provides a firm base upon which, with careful attention to regulation of blood glucose, reduction of hypertensive blood pressure, and provision of emotional support, a new, tenuous life may be built.
在过去十年中,不断有报告称不可逆肾衰竭糖尿病患者的生存率和康复情况有所改善。然而,对于尿毒症糖尿病患者,尚未有关于持续性非卧床腹膜透析(CAPD)、维持性血液透析或肾移植相对优点的对照前瞻性试验。一般来说,较年轻、更具康复潜力的糖尿病患者会接受肾移植,而年龄较大、病情通常较重的糖尿病患者则接受CAPD治疗,大多数糖尿病患者则接受维持性血液透析治疗。治疗选择合理地基于团队经验和可用设施。此外,患者选择标准和尿毒症治疗开始时间不一致,妨碍了对一系列接受治疗的糖尿病患者进行直接比较。虽然近年来接受维持性血液透析或腹膜透析治疗的糖尿病患者的生存率有了显著提高,但肾移植后的生存率和康复情况优于其他形式的尿毒症治疗。累积数据表明,接受治疗的尿毒症糖尿病患者接受血液透析有50%的机会存活3年,如果接受功能良好的尸体肾移植,有50%的机会存活5年,如果移植功能良好的亲属活体肾,预期50%的患者能存活7.5年甚至更长时间。使用与患者人类白细胞抗原(HLA)相同的同胞供肾可能会取得更好的效果,特别是在早期移植并使用环孢素而非硫唑嘌呤时,这样可以将类固醇剂量降至最低水平。当由精通糖尿病综合管理的团队谨慎进行肾移植时,是尿毒症糖尿病患者的首选治疗方法。然而,透析治疗具有显著价值,不仅可作为移植禁忌或无肾患者的替代治疗,还可作为等待手术干预期间的维持生命治疗。无论采用何种治疗方法,糖尿病肾病都不应再被视为绝望的疾病。不幸的是,为糖尿病患者提供替代其自身肾功能的方法本身并不能减少已存在的多系统微血管和大血管疾病的进展。在患有肾视网膜综合征的衰竭糖尿病患者中植入功能良好的肾移植,在此基础上,通过仔细关注血糖调节、降低高血压以及提供情感支持,可以构建新的、脆弱的生活。